Abstract:Mucosal barrier tissues and their mucosal associated lymphoid tissues (MALT) are attractive targets for vaccines and immunotherapies due to their roles in both priming and regulating adaptive immune responses. The upper and lower respiratory mucosae, in particular, possess unique properties: a vast surface area responsible for frontline protection against inhaled pathogens but also simultaneous tight regulation of homeostasis against a continuous backdrop of non-pathogenic antigen exposure. Within the upper and lower respiratory tract, the nasal and bronchial associated lymphoid tissues (NALT and BALT, respectively) are key sites where antigen-specific immune responses are orchestrated against inhaled antigens, serving as critical training grounds for adaptive immunity. Many infectious diseases are transmitted via respiratory mucosal sites, highlighting the need for vaccines that can activate resident frontline immune protection in these tissues to block infection. While traditional parenteral vaccines that are injected tend to elicit weak immunity in mucosal tissues, mucosal vaccines (i.e., that are administered intranasally) are capable of eliciting both systemic and mucosal immunity in tandem by initiating immune responses in the MALT. In contrast, administering antigen to mucosal tissues in the absence of adjuvant or costimulatory signals can instead induce antigen-specific tolerance by exploiting regulatory mechanisms inherent to MALT, holding potential for mucosal immunotherapies to treat autoimmunity. Yet despite being well motivated by mucosal biology, development of both mucosal subunit vaccines and immunotherapies has historically been plagued by poor drug delivery across mucosal barriers, resulting in weak efficacy, short-lived responses, and to-date a lack of clinical translation. Development of engineering strategies that can overcome barriers to mucosal delivery are thus critical for translation of mucosal subunit vaccines and immunotherapies. This review covers engineering strategies to enhance mucosal uptake via active targeting and passive transport mechanisms, with a parallel focus on mechanisms of immune activation and regulation in the respiratory mucosa. By combining engineering strategies for enhanced mucosal delivery with a better understanding of immune mechanisms in the NALT and BALT, we hope to illustrate the potential of these mucosal sites as targets for immunomodulation.

Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin

Dissolving Microneedle Delivery of Nanoparticle-Encapsulated Antigen Elicits Efficient Cross-Priming and Th1 Immune Responses by Murine Langerhans Cells

Targeting of the C-Type Lectin Receptor Langerin Using Bifunctional Mannosylated Antigens

Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets

Influenza Virus-Like Particles Coated Onto Microneedles Can Elicit Stimulatory Effects on Langerhans Cells in Human Skin

Zwitterionic Peptide Pendant As a Homing Agent to Achieve Lymphatic Targeting Antigen-Specific Immunotherapy of Allergenic Protein

Intra-Lymph Node Crosslinking of Antigen-Bearing Polymers Enhances Humoral Immunity and Dendritic Cell Activation

In vivo/ex vivo targeting of Langerhans cells after topical application of the immune response modifier TMX-202: confocal Raman microscopy and histology analysis

Transdermal microneedles integrating biomimetic self-adjuvant particles for enhanced immunity

Microneedle-based two-step transdermal delivery of Langerhans cell-targeting immunoliposomes induces a Th1-biased immune response

Intra‐lymph node crosslinking of antigen‐bearing polymers enhances humoral immunity and dendritic cell activation

Antigen-loaded Flagellate Bacteria for Enhanced Adaptive Immune Response by Intradermal Injection.

Incorporating immune cell surrogates into a full-thickness tissue equivalent of human skin to characterize dendritic cell activation

Designing a therapeutic SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups

Development of a skin-friendly microemulsion for dermal allergen-specific immunotherapy

Lipid-Polymer Hybrid Nanoparticles Utilize B Cells and Dendritic Cells to Elicit Distinct Antigen-Specific CD4+ and CD8+ T Cell Responses

Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake

Femtosecond two-photon high-resolution 3D imaging, spatial-volume rendering and microspectral characterization of immunolocalized MHC-II and mLangerin/CD207 antigens in the mouse epidermis

DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response

In Vivo Stimulation of Therapeutic Antigen‐Specific T Cells in an Artificial Lymph Node Matrix (Adv. Mater. 23/2024)

Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity.